A glossary of circulating cytokines in chronic heart failure.
about
The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist.A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?Present and future pharmacotherapy for heart failure.Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart.Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure.Psychobiology of depression/distress in congestive heart failureVitamin D deficiency contributes to the reduction and impaired function of naïve CD45RA⁺ regulatory T cell in chronic heart failureEstrogen receptor α mediates the effects of notoginsenoside R1 on endotoxin-induced inflammatory and apoptotic responses in H9c2 cardiomyocytes.Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failureDepression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches.Levosimendan for the treatment of acute heart failure syndromes.Sertraline for the treatment of depression in coronary artery disease and heart failure.Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failureMorphological and molecular changes of the myocardium after left ventricular mechanical supportPharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.A Central Role for Monocyte-Platelet Interactions in Heart Failure.Neurohumoral improvement and torsional dynamics in patients with heart failure after treatment with levosimendan.Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.Early inflammatory response during the development of right ventricular heart failure in a rat model.Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure.CA 125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis.Skeletal muscle myofibrillar protein metabolism in heart failure: relationship to immune activation and functional capacity.The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.Biventricular versus right ventricular pacing decreases immune activation and augments nitric oxide production in patients with chronic heart failure.Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study.Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure.Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?The Cardioprotective Effects of 4-O-(2″-O-acetyl-6″-O- P-coumaroyl-β-D-glucopyranosyl)-P-coumaric Acid (4-ACGC) on Chronic Heart Failure.Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanismsInflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial
P2860
Q30320708-2397288F-5A43-435D-8F69-88F94F65F4EEQ34473637-AFC41C74-C955-4997-9F45-8F5D5FB2B393Q34706912-F2092AC6-1DB7-453B-8913-687E43F6EBF0Q35026157-F5EE6ECE-D2C7-4AA9-8E16-3450442A4451Q35057082-DC9AACE2-649F-4593-A728-4EC531AD96F9Q35293910-F16E4402-C0F4-436E-A228-F0C1A78DA6CDQ35578732-04AEB56D-30D5-4E08-9F12-72A7ACD3A435Q35628334-8A1B23F3-59F2-4909-81EA-9F6811913119Q35772807-B47D87AB-4436-4410-8FC2-595BD21429F5Q36145832-EE2EBDC0-F514-4C4A-94D9-0395F4177C5CQ36326272-422CF615-F246-45CE-A488-14C8063A5CA9Q36895857-48BB2196-88AC-4BD3-A785-22789A3C0478Q37090965-424768CA-D510-4F62-89ED-29A11C9752DAQ37638247-16F61735-0492-4A96-8564-144F63010EFDQ38099679-955DED32-5BC2-4A8A-B968-BEFD039B0B04Q38134311-6EFCB573-9AB8-43E5-92FD-67B06E7A4D77Q38620927-2CA43EC7-7FE7-45F7-A683-3E309D551B89Q40964343-5D691964-3008-4C97-B0E9-B1862CDF66D4Q42653967-B616AC23-C84A-45A5-9EAB-12797EB0E9FFQ43056274-FFB493BD-B002-4819-80F5-0F86CE15F895Q44025446-6C0008CB-2861-4D96-8C58-F2140F8555D0Q44526003-89FEF71A-37E5-4507-8A78-CDA5EFEC6659Q45161616-319B35E1-A46B-42A8-9494-2F732EE91DB1Q46515116-1F446F77-B567-48F5-ADBB-1C8EB200A356Q46624363-D6690003-D6A5-4765-8659-6CEBF48899FDQ46932873-77774F2D-EB34-44A7-9529-8491B24BBD7BQ48312808-A167FBEB-1388-47BF-AEE9-D51DB88F9394Q48446603-7E08A083-D703-4E41-A915-3110C69BF21CQ48666150-89127D6D-964B-4923-A634-0EB0B2436D44Q51741939-49D0B18D-726F-4049-87DB-A718BC5E8357Q54976732-B752A08F-D2C0-4D49-AFA9-6EDA7336FA89Q57805266-D6B84140-3DF6-450E-B7D4-B2422101D46BQ58854099-F7B98C5E-23D9-4E19-849C-CB4E708952AE
P2860
A glossary of circulating cytokines in chronic heart failure.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A glossary of circulating cytokines in chronic heart failure.
@ast
A glossary of circulating cytokines in chronic heart failure.
@en
A glossary of circulating cytokines in chronic heart failure.
@nl
type
label
A glossary of circulating cytokines in chronic heart failure.
@ast
A glossary of circulating cytokines in chronic heart failure.
@en
A glossary of circulating cytokines in chronic heart failure.
@nl
prefLabel
A glossary of circulating cytokines in chronic heart failure.
@ast
A glossary of circulating cytokines in chronic heart failure.
@en
A glossary of circulating cytokines in chronic heart failure.
@nl
P2093
P2860
P1476
A glossary of circulating cytokines in chronic heart failure.
@en
P2093
Adamopoulos S
Kremastinos DT
Parissis JT
P2860
P304
P356
10.1016/S1388-9842(01)00156-8
P577
2001-10-01T00:00:00Z